Parker Waichman LLP Headlines by Topic
Tekturna
Blood Pressure Medication Tekturna Linked to Potentially Deadly Complications, Says Public Safety Group
Nov 1, 2012
Parker Waichman LLP is reporting that Tekturna, a drug used to treat hypertension, is associated with potentially fatal side effects. According...
Novartis Updating Tekturna Label with Warnings for Diabetes, Kidney Patients. Announces Valturna Market Withdrawal.
Apr 20, 2012
| Parker Waichman LLP
Novartis has announced that it will be making changes to the labels for Tekturna and other aliskiren-based medications regarding serious risks posed...
U.K. Regulator Issues Aliskiren (Rasilez and Tekturna) Update
Mar 9, 2012
| Parker Waichman LLP
U.K.'s health regulator has issued a Drug Safety Update detailing new contraindications for diabetics and kidney patients using the blood pressure...
Novartis Agrees to New Rasilez Warnings
Feb 20, 2012
| Parker Waichman LLP
Following the halt of the ALTITUDE trial, Novartis has agreed to comply with a request by European regulators change the label for its blood pressure...
Page 1/1



